SANTA CLARA, Calif., Feb. 8, 2011 /PRNewswire/ — NewCardio,
Inc., (OTC Bulletin Board:
NWCI) a cardiovascular diagnostic solutions developer,
announced today that the Company has been invited to present the
results of a key QTinno® performance study at the National
Scientific Meeting of the American Society of Clinical Pharmacology
and Therapeutics (ASCPT), to be held in Dallas, March 3-5,
2011.
The study, entitled “Intelligent Automated ECG Extraction from
Continuous 12-Lead Holter Recordings Reduces Measurement
Variability in Thorough QT Studies,” was completed in collaboration
with physician scientists from a global pharmaceutical partner.
Continuous 24-hour ECG recordings (Holters) are commonly used in
cardiac safety drug studies. At present, the user visually
selects three 10 second ECGs from the recording within 5 minutes of
each designated study time point, a labor-intensive approach that
is prone to error and variability. NewCardio has developed a novel
ECG selection algorithm that evaluates the entire 10-minute window
around the designated time point and selects the lowest noise and
most stable ECGs in the window. The study chosen for presentation
at the ASCPT meeting shows NewCardio’s automated ECG selection
method yields substantially more accurate and precise data than
visual ECG selection. Moreover, the accuracy gain from
automated ECG selection is fully additive to the accuracy gain
delivered by QTinno itself.
Dr. Ihor Gussak, NewCardio’s Chief Medical Officer, commented,
“We are pleased to have this opportunity to present our results on
automated ECG selection at the annual ASCPT meeting. This is a
prestigious and well-attended forum, and gives us an excellent
opportunity to share our latest QTinno improvements and innovations
with scientists and professionals from academia, drug regulatory
bodies, clinical trial service providers, and
‘/>”/>
